Immuron Limited is today pleased to announce the topline results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. The results show that oral IMM-124E shows improvement in liver injury with the potential for far-reaching opportunities beyond NASH.
After further assessment, Red Chip analyst upgrades Immuron on C-Difficile Trial Result.
Completion of C. Difficile pre-clinical proof-of-concept yields outstanding efficacy results.
See Immuron CEO, Thomas Liquard's presentation for Red Chip Global Online CEO Conference